NutraCast: Akkermansia research points to postbiotic potential for metabolic health, weight maintenance

Exploring how microbiome science and prebiotic innovation are shaping the future of gut and metabolic health.
Professor Willem de Vos explores Akkermansia research, postbiotic benefits, metabolic health and the potential to support long-term weight maintenance. (William Reed)

After more than 20 years of research, Akkermansia muciniphila has emerged as a key area of interest in microbiome science, with growing evidence suggesting potential benefits for metabolic health, gut barrier function and weight maintenance.

Professor Willem de Vos of Wageningen University in the Netherlands, who discovered the bacterium, discusses how the science has evolved and what comes next.

De Vos first isolated the mucus-degrading bacterium while investigating microbes that naturally colonize the human gut. Subsequent research repealed its role in immune and metabolic signaling, including improvements in intestinal barrier function.

“I anticipated Akkermansia to be important as we feed it ourselves to grow,” he explained. “But we actually established that we feed it, and it talks to us.”

Clinical trials have since shown promising results. Case in point: one study found that three months of supplementation with pasteurized A. muciniphila MucT improved insulin sensitivity, reduced weight and trunk fat in overweight and prediabetic participants. Another, published in Nature Medicine, demonstrated potential for maintaining weight loss over a six-month intervention.

A key development was the discovery that pasteurized cells could be just as effective as live bacteria.

“We show that the pasteurized cells are as active or even more active than the live cells,” said de Vos, pointing to a specific thermostable protein, Amuc_1100, believed to play an important role in the ingredient’s activity.

With growing interest in GLP-1 medications, de Vos sees another opportunity for the postbiotic supporting weight maintenance following weight loss.

Explore related questions

“You do not want to use these drugs all the time,” he said, highlighting the potential to help address weight regain after treatment stops.

Looking ahead, de Vos hopes to see more research in early-life microbiome development, childhood obesity and the potential role of Akkermansia in the gut-brain axis.

To hear more about the science behind Akkermansia muciniphila, how the bacterium got its name, the growing interest in postbiotics and what’s next for microbiome research, listen to the NutraCast above or on your preferred podcast platform.

If you enjoy listening to the NutraCast, feel free to leave a review. You can subscribe on Apple, iHeart, Spotify or wherever you get your podcasts.